Reply to G Taubes, MI Friedman, and V Torres-Carot et al.

Kevin D. Hall; I. Sadaf Farooqi; Jeffery M. Friedman; Samuel Klein; Ruth J.F. Loos; David J. Mangelsdorf; Stephen O’Rahilly; Eric Ravussin; Leanne M. Redman; Donna H. Ryan; John R. Speakman; Deirdre K. Tobias

doi:10.1093/ajcn/nqac163

Reply to G Taubes, MI Friedman, and V Torres-Carot et al.

Kevin D. Hall^* (Corresponding Author), I. Sadaf Farooqi, Jeffery M. Friedman, Samuel Klein, Ruth J.F. Loos, David J. Mangelsdorf, Stephen O’Rahilly, Eric Ravussin, Leanne M. Redman, Donna H. Ryan, John R. Speakman, Deirdre K. Tobias

^*Corresponding author for this work

Research output: Contribution to journal › Letter › peer-review

1 Citation (Scopus)

Abstract

In our recent Perspective (1), we described Taubes’ 2007 carbohydrate-insulin model (CIM) as positing that:
obesity results from increased dietary carbohydrates driving excess insulin secretion causing adipose tissue to accumulate and trap fat thereby starving nonadipose tissues of fuel. Thus, “by driving fat accumulation, carbohydrates also increase hunger and decrease the amount of energy we expend in metabolism and physical activity” (2) thereby resulting in positive energy balance with energy intake exceeding expenditure.

Original language	English
Pages (from-to)	614-615
Number of pages	2
Journal	American Journal of Clinical Nutrition
Volume	116
Issue number	2
Early online date	8 Jun 2022
DOIs	https://doi.org/10.1093/ajcn/nqac163
Publication status	Published - Aug 2022

Bibliographical note

Funding Information:
Supported by NIH grant 1ZIADK013037 (to KDH). KDH has participated in several debates with David S Ludwig on theories of obesity and has received funding from the Nutrition Science Initiative to test predictions of the CIM. JMF reports royalty payments for leptin for the treatment of lipodystrophy. SK serves as a scientific consultant for Altimmune, Janssen, and B2M and has a sponsored research agreement with Janssen. SOR receives remuneration for scientific advice from Pfizer, AstraZeneca, and ThirdRock Ventures. DHR reports personal fees from Altimmune, Amgen, Gila Therapeutics, Phenomix, Quintiles, Rhythm, YSOPIA, Zealand, Lilly, and Wondr Health, and Roman Health, and personal fees and nonfinancial support from Boeringer Ingelheim, Calibrate, Epitomee, IFA Celtic, Janssen, Novo Nordisk, real appeal (United Health Care), Sanofi, Scientific Intake, and Xeno Bioscience, outside the submitted work. All other authors report no conflicts of interest.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/ajcn/nqac163Licence: Other

Cite this

@article{67df5e4cefb542e4b5e7edf6b18b853c,

title = "Reply to G Taubes, MI Friedman, and V Torres-Carot et al.",

abstract = "In our recent Perspective (1), we described Taubes{\textquoteright} 2007 carbohydrate-insulin model (CIM) as positing that:obesity results from increased dietary carbohydrates driving excess insulin secretion causing adipose tissue to accumulate and trap fat thereby starving nonadipose tissues of fuel. Thus, “by driving fat accumulation, carbohydrates also increase hunger and decrease the amount of energy we expend in metabolism and physical activity” (2) thereby resulting in positive energy balance with energy intake exceeding expenditure.",

author = "Hall, {Kevin D.} and Farooqi, {I. Sadaf} and Friedman, {Jeffery M.} and Samuel Klein and Loos, {Ruth J.F.} and Mangelsdorf, {David J.} and Stephen O{\textquoteright}Rahilly and Eric Ravussin and Redman, {Leanne M.} and Ryan, {Donna H.} and Speakman, {John R.} and Tobias, {Deirdre K.}",

note = "Funding Information: Supported by NIH grant 1ZIADK013037 (to KDH). KDH has participated in several debates with David S Ludwig on theories of obesity and has received funding from the Nutrition Science Initiative to test predictions of the CIM. JMF reports royalty payments for leptin for the treatment of lipodystrophy. SK serves as a scientific consultant for Altimmune, Janssen, and B2M and has a sponsored research agreement with Janssen. SOR receives remuneration for scientific advice from Pfizer, AstraZeneca, and ThirdRock Ventures. DHR reports personal fees from Altimmune, Amgen, Gila Therapeutics, Phenomix, Quintiles, Rhythm, YSOPIA, Zealand, Lilly, and Wondr Health, and Roman Health, and personal fees and nonfinancial support from Boeringer Ingelheim, Calibrate, Epitomee, IFA Celtic, Janssen, Novo Nordisk, real appeal (United Health Care), Sanofi, Scientific Intake, and Xeno Bioscience, outside the submitted work. All other authors report no conflicts of interest.",

year = "2022",

month = aug,

doi = "10.1093/ajcn/nqac163",

language = "English",

volume = "116",

pages = "614--615",

journal = "American Journal of Clinical Nutrition",

issn = "0002-9165",

publisher = "American Society for Nutrition",

number = "2",

}

TY - JOUR

T1 - Reply to G Taubes, MI Friedman, and V Torres-Carot et al.

AU - Hall, Kevin D.

AU - Farooqi, I. Sadaf

AU - Friedman, Jeffery M.

AU - Klein, Samuel

AU - Loos, Ruth J.F.

AU - Mangelsdorf, David J.

AU - O’Rahilly, Stephen

AU - Ravussin, Eric

AU - Redman, Leanne M.

AU - Ryan, Donna H.

AU - Speakman, John R.

AU - Tobias, Deirdre K.

N1 - Funding Information: Supported by NIH grant 1ZIADK013037 (to KDH). KDH has participated in several debates with David S Ludwig on theories of obesity and has received funding from the Nutrition Science Initiative to test predictions of the CIM. JMF reports royalty payments for leptin for the treatment of lipodystrophy. SK serves as a scientific consultant for Altimmune, Janssen, and B2M and has a sponsored research agreement with Janssen. SOR receives remuneration for scientific advice from Pfizer, AstraZeneca, and ThirdRock Ventures. DHR reports personal fees from Altimmune, Amgen, Gila Therapeutics, Phenomix, Quintiles, Rhythm, YSOPIA, Zealand, Lilly, and Wondr Health, and Roman Health, and personal fees and nonfinancial support from Boeringer Ingelheim, Calibrate, Epitomee, IFA Celtic, Janssen, Novo Nordisk, real appeal (United Health Care), Sanofi, Scientific Intake, and Xeno Bioscience, outside the submitted work. All other authors report no conflicts of interest.

PY - 2022/8

Y1 - 2022/8

N2 - In our recent Perspective (1), we described Taubes’ 2007 carbohydrate-insulin model (CIM) as positing that:obesity results from increased dietary carbohydrates driving excess insulin secretion causing adipose tissue to accumulate and trap fat thereby starving nonadipose tissues of fuel. Thus, “by driving fat accumulation, carbohydrates also increase hunger and decrease the amount of energy we expend in metabolism and physical activity” (2) thereby resulting in positive energy balance with energy intake exceeding expenditure.

AB - In our recent Perspective (1), we described Taubes’ 2007 carbohydrate-insulin model (CIM) as positing that:obesity results from increased dietary carbohydrates driving excess insulin secretion causing adipose tissue to accumulate and trap fat thereby starving nonadipose tissues of fuel. Thus, “by driving fat accumulation, carbohydrates also increase hunger and decrease the amount of energy we expend in metabolism and physical activity” (2) thereby resulting in positive energy balance with energy intake exceeding expenditure.

UR - http://www.scopus.com/inward/record.url?scp=85135596778&partnerID=8YFLogxK

U2 - 10.1093/ajcn/nqac163

DO - 10.1093/ajcn/nqac163

M3 - Letter

C2 - 35675318

AN - SCOPUS:85135596778

SN - 0002-9165

VL - 116

SP - 614

EP - 615

JO - American Journal of Clinical Nutrition

JF - American Journal of Clinical Nutrition

IS - 2

ER -

Reply to G Taubes, MI Friedman, and V Torres-Carot et al.

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this